English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduChildren’s Hospital Los Angeles faculty will present their latest research on pediatric blood cancers and diseases at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.The annual conference—billed as the world’s largest and most comprehensive hematology event—will take place Dec. 7-10. In 2023, ASH attracted more than 32,000 attendees from over 100 countries.
Tag: Pediatric Cancer
Children’s Brain Tumor Network Dataset Now Accessible on Kids First Data Resource Center Portal
The Gabriella Miller Kids First Data Resource Center (Kids First DRC) announces the addition of the full Children’s Brain Tumor Network (CBTN) dataset to the Kids First DRC portal.
Channeling Challenge Into Community: Hunter’s Story
Hunter doesn’t remember much from his time at Children’s Hospital Los Angeles, but more than a decade later, one small moment has stuck with him in multiple ways.A blonde woman asks him: “She’d hold up an array of ChapSticks,” Hunter explains, “blueberry, strawberry, green apple, root beer float and chocolate.”
Researchers from IRB Barcelona and Sant Joan de Déu unveil the origin of second pediatric cancers and chemotherapy-induced mutations in healthy tissues
A team from IRB Barcelona and Sant Joan de Déu Hospital · IRSJD has studied the cases of four children who have experienced two cancers during childhood and has addressed the origin of the second tumour.
St. Baldrick’s Foundation Awards $50,000 Grant to Expand Pediatric Cancer Clinical Trials at K. Hovnanian Children’s Hospital
St. Baldrick’s Foundation Awards $50,000 Grant to Expand Pediatric Cancer Clinical Trials at K. Hovnanian Children’s Hospital
U of T-led study finds positive support from parents and clinicians for pediatric cancer pain management app
A recent study led by Assistant Professor Lindsay Jibb of the Lawrence Bloomberg Faculty of Nursing and Scientist at The Hospital for Sick Children (SickKids) found that parents of young children with cancer, along with pediatric cancer clinicians are in favour of an app-based solution that Jibb and her team are creating, to help parents manage their child’s cancer pain at home.
Sara Federico, MD, named director of the Solid Tumor Division at St. Jude Children’s Research Hospital
Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.
Five Questions Parents Should Ask Their Child’s Oncologist About Participating in a Clinical Trial
When children undergo cancer treatment, they may be offered the chance to participate in a clinical trial. Clinical trials can provide access to new, groundbreaking therapies in a safe and controlled environment.
NCCN Senior Director Evelyn Handel Zapata is Named a ‘40 Under 40 in Cancer: Emerging Leader’ for Milestone Work Improving Safe Use of Chemotherapy
Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader; launches new resources for a type of pediatric lymphoma.
The Tiny Fish With Big Impact
The zebrafish is one of the most powerful biomedical research tools in use today. Children’s Hospital Los Angeles is using them to better understand what causes pediatric cancer.
NCCN Releases New Resource to Help Families Understand Pediatric Hodgkin Lymphoma, Part of Award-Winning Patient Information Series
The National Comprehensive Cancer Network (NCCN) today announces the publication of NCCN Guidelines for Patients: Hodgkin Lymphoma in Children.
St. Jude shows cancer resistance protein can have its cake and eat it too
Scientists at St. Jude Research Hospital unravel the mechanisms behind a key culprit in chemotherapy resistance.
Penn State Health Children’s Hospital, Penn State College of Medicine bring international research consortium to Hershey to strengthen their fight against childhood cancer
Penn State Health and Penn State College of Medicine are strengthening their commitment to curing childhood cancer by bringing Dr. Giselle Saulnier Sholler, an internationally known physician-scientist, and her research consortium to Hershey.
Children’s Hospital Los Angeles: La Mejor Atención Pediátrica en California y la Región del Pacífico de los EE.UU.
CHLA vuelve a ser el hospital pediátrico Nro. 1 en su estado natal de California y en el Pacífico de los Estados Unidos, una región que incluye todos los estados a lo largo de la Costa Oeste, incluido Hawái. CHLA también ascendió al Nro. 7 en general a nivel nacional en el Cuadro de Honor de los Mejores Hospitales Infantiles de este año, el estándar de oro de los principales destinos para la atención pediátrica, y está clasificado a nivel nacional en las 10 subespecialidades pediátricas evaluadas, incluido el Nro. 2 en los EE. UU. en ortopedia, Nro. 3 en cáncer y Nro. 5 en gastroenterología y cirugía GI.
Healthy lifestyle associated with reduced mortality risk in childhood cancer survivors
St. Jude Children’s Research Hospital researchers found childhood cancer survivors have higher mortality than the public, but survivors with a healthy lifestyle and fewer heart disease risk factors had lower risk.
St. Jude tool targets cancer-causing fusions’ weak spot
Scientists at St. Jude Children’s Research Hospital comprehensively characterized oncogenic fusions in pediatric cancer, providing proof-of-principle for genetic engineering-based therapies.
Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.
For Children With Cancer, Different Neighborhoods May Produce Different Outcomes for Different Races
A Rutgers study links zip code and cancer complication disparities in pediatric patients.
St. Jude scientists create more efficient CAR immunotherapies using a molecular anchor
St. Jude scientists added a small physical structure called an anchor domain to the CAR molecule. The anchor domain connects the CAR to the internal infrastructure of the immune cell. It augments and helps organize the immune synapse
International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children’s Cancers
NCCN is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.
Mount Sinai Researchers Find New, Safer Treatment for Serious Side Effect of Bone Marrow Transplant
Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer patients. Results from a phase 2 clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) in December.
Three of the world’s top research institutions join forces to drive progress against pediatric cancer
Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.
Rhombic lip implicated in origins of high-risk medulloblastoma
Scientists from St. Jude Children’s Research Hospital found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may help improve research models and therapeutic development.
To wipe childhood cancer off the map, scientists must chart its genomic landscape
Scientists at St. Jude sequenced more samples of the most common childhood cancer than ever before to fully characterize the potential mutations driving disease.
SAFER Ukraine provides a blueprint for responding to global health crises
Russia’s invasion of Ukraine created a dire situation for children with cancer and blood disorders. In response, the St. Jude Global initiative of St. Jude Children’s Research Hospital banded together with international partners and formed SAFER Ukraine. An account appears in The Lancet Haematology.
Children’s Hospital Los Angeles Finds Differences in How Doctors, Caregivers and Patients Report Side Effects of Cancer Therapy
A recent study reveals differences in how in symptom toxicity is reported for children receiving cancer treatment in clinical trials. Doctors often underestimate or miss a child’s symptoms, while caregivers tend to overestimate symptoms.
Dana-Farber/Boston Children’s again named top pediatric cancer program
U.S. News &World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children’s Hospitals report. Dana-Farber/Boston Children’s has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking’s inception, earning more #1 rankings than any other program.
Children’s Hospital Los Angeles： 美国加州和太平洋地区最好的儿童护理机构
《美国新闻与世界报道》再次将 CHLA 评为其本州加利福尼亚州和美国太平洋地区（包括阿拉斯加州、加利福尼亚州、夏威夷州、俄勒冈州和华盛顿州）的最佳儿童医院。CHLA 还连续 14 年（自该排名诞生以来从未缺席）入选该刊年度“最佳儿童医院榜”——美国领先儿科机构权威榜单——最终名列第 8 位。
Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Cure 10 Years Later
Ten years ago, Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so rapidly that she was ineligible for a bone marrow transplant to treat it. Her family came to CHOP in the hopes that Dr. Stephan Grupp, a pioneer in the field of cellular immunotherapy, could provide the miracle they were looking for.
Team TKC Captain Eli Manning Kicks Off Second Annual Virtual Race to Tackle Kids Cancer
#TeamTKC Captain Eli Manning Kicks Off Second Annual Virtual Race to Tackle Kids Cancer
Combining Two ‘Old Therapies’ Packs a Powerful Punch Against Pediatric Brain Tumors
Researchers at Johns Hopkins Medicine and Italy’s Catholic University of the Sacred Heart medical school have provided solid evidence that copper, the first metal used medicinally, may now have a new role — helping save children from a devastating central nervous system cancer known as medulloblastoma.
CHOP Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers
In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches, the researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with “peptide-centric” chimeric antigen receptors (PC-CARs), a new class of engineered T cells, stimulating an immune response that eradicates tumors.
Cell-free DNA identifies early signs of relapse in pediatric medulloblastoma
Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
The Medical Minute: On the watch for pediatric cancers
No parent wants to hear the word “cancer.” Fortunately, few will, but it’s always smart to be attuned to signs that might warrant a further look. Two Penn State Health Children’s Hospital doctors discuss the warning signs.
International collaboration helps refine treatment for childhood leukemia
Results from a large phase 3 noninferiority clinical trial definitively showed that vincristine and dexamethasone pulses can be eliminated in patients with low-risk disease. The findings were published today in The Lancet Oncology.
Heated chemotherapy can help some children with cancer
Known as HIPEC, the therapy has been available for adults for years at Michigan Medicine. Now it’s an option for kids here, too.
Comprehensive clinical sequencing opens door to the promise of precision medicine
St. Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer.
Scientists link frailty and neurocognitive decline in childhood cancer survivors
St. Jude Children’s Research Hospital scientists have shown that frailty contributes to neurocognitive decline in young adult survivors of childhood cancer.
Melanoma registry results shine light on rare pediatric cancer
St. Jude Children’s Research Hospital scientists created a registry for molecular analysis of pediatric melanoma that provides insight into treatment.
#TeamTKC Captain Eli Manning Helps Launch Inaugural Virtual 5K to Tackle Kids Cancer
#TeamTKC Captain Eli Manning Helps Launch Inaugural Virtual 5K to Tackle Kids Cancer
Low-calorie diet and mild exercise improve survival for young people with leukemia
A study led by researchers at UCLA and CHLA has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.
Cecelia Calhoun Named Director of the Adolescent-Young Adult Sickle Cell Program at Yale Cancer Center and Smilow Cancer Hospital
Cecelia Calhoun, MD, MSPH, MBA, has been appointed Assistant Professor of Medicine (Hematology) and Assistant Professor of Pediatrics (Hematology/Oncology) at Yale Cancer Center and Smilow Cancer Hospital
ATRT molecular groups: looking at the biology from the clinic
Scientists at St. Jude Children’s Research Hospital are learning more about what the molecular groups of a rare pediatric brain tumor mean for clinical care.
Alex’s Lemonade Stand Foundation Awards More than $18.5 Million to Recipients of Crazy 8 Initiative to Advance Pediatric Cancer Research
In the spirit of growing scientific collaboration, grants will provide support for four projects across 15 research institutions using cutting-edge technology to address crucial issues in pediatric cancer research
Socioeconomic status plays a major role in cognitive outcomes
Childhood cancer and its treatment can result in cognitive struggles. St. Jude scientists are studying the risk factors.
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
Study reveals mutations that drive therapy-related myeloid neoplasms in children
Research from scientists at St. Jude Children’s Research Hospital found mutations up to two years before cancer developed, showing an opportunity for early interventions.
From the clinic to the lab, understanding medulloblastoma relies on molecular profiling
A pair of research papers from St. Jude Children’s Research Hospital report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors
In a large study of pediatric cancer patients, researchers from Children’s Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.
Hackensack Meridian Health’s Tackle Kids Cancer Celebrates Five Years of Support to Fight Pediatric Cancer and Raises more than $10 Million
Philanthropic initiative of the Children’s Cancer Institute, reaches five year milestone combatting pediatric cancer